Monday, October 24, 2016

Raltitrexed




Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

L01BA03

CAS registry number (Chemical Abstracts Service)

0112887-68-0

Chemical Formula

C21-H22-N4-O6-S

Molecular Weight

458

Therapeutic Category

Antineoplastic agent

Chemical Name

L-Glutamic acid, N-[5-[[(3,4-dihydro-2-methyl-4-oxo-6-quinazolinyl)methyl]methylamino]-2-thenoyl]-

Foreign Names

  • Raltitrexedum (Latin)
  • Raltitrexed (German)
  • Raltitrexed (French)
  • Raltitrexed (Spanish)

Generic Names

  • Raltitrexed (OS: USAN, BAN)
  • D 1694 (IS: Zeneca)
  • ICI-D 1694 (IS: Zeneca)
  • Paltitrexid (IS)
  • ZD 1694 (IS: Zeneca)
  • ZN-D 1694 (IS: Zeneca)

Brand Names

  • Tomudex
    AstraZeneca, United Arab Emirates; AstraZeneca, Argentina; AstraZeneca, Belgium; AstraZeneca, Bahrain; AstraZeneca, Brazil; AstraZeneca, Canada; AstraZeneca, Costa Rica; AstraZeneca, Czech Republic; AstraZeneca, Dominican Republic; AstraZeneca, Egypt; AstraZeneca, Spain; AstraZeneca, France; AstraZeneca, Georgia; AstraZeneca, Guatemala; AstraZeneca, Guyana; AstraZeneca, Honduras; AstraZeneca, Hungary; AstraZeneca, Ireland; AstraZeneca, Iraq; AstraZeneca, Iran; AstraZeneca, Iceland; AstraZeneca, Italy; AstraZeneca, Jordan; AstraZeneca, Kuwait; AstraZeneca, Lebanon; AstraZeneca, Latvia; AstraZeneca, Nicaragua; AstraZeneca, Norway; AstraZeneca, Oman; AstraZeneca, Panama; AstraZeneca, Peru; AstraZeneca, Portugal; AstraZeneca, Qatar; AstraZeneca, Russian Federation; AstraZeneca, Saudi Arabia; AstraZeneca, Singapore; AstraZeneca, El Salvador; AstraZeneca, Syria; AstraZeneca, Turkey; AstraZeneca, Yemen; Hospira, Austria; Hospira, Australia; Hospira, Switzerland; Hospira, United Kingdom; Hospira, Luxembourg

International Drug Name Search

Glossary

BANBritish Approved Name
ISInofficial Synonym
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.

No comments:

Post a Comment